# A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

> **NCT06668103** · PHASE2 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer With EGFR Mutation

## Interventions

- **DRUG:** ABSK043 in combination with Firmonertinib

## Key facts

- **NCT ID:** NCT06668103
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668103, "A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06668103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*